Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT).
Serruys PW, Rutsch W, Heyndrickx GR, Danchin N, Mast EG, Wijns W, Rensing BJ, Vos J, Stibbe J. Serruys PW, et al. Among authors: rensing bj. Circulation. 1991 Oct;84(4):1568-80. doi: 10.1161/01.cir.84.4.1568. Circulation. 1991. PMID: 1833088 Clinical Trial.
Therapeutic dissection after successful coronary balloon angioplasty: no influence on restenosis or on clinical outcome in 693 patients. The MERCATOR Study Group (Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis).
Hermans WR, Rensing BJ, Foley DP, Deckers JW, Rutsch W, Emanuelsson H, Danchin N, Wijns W, Chappuis F, Serruys PW. Hermans WR, et al. Among authors: rensing bj. J Am Coll Cardiol. 1992 Oct;20(4):767-80. doi: 10.1016/0735-1097(92)90171-i. J Am Coll Cardiol. 1992. PMID: 1388181 Free article. Clinical Trial.
Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
Hermans WR, Rensing BJ, Foley DP, Tijssen JG, Rutsch W, Emanuelsson H, Danchin N, Wijns W, Chappuis F, Serruys PW. Hermans WR, et al. Among authors: rensing bj. J Cardiovasc Pharmacol. 1993;22 Suppl 4:S45-57. J Cardiovasc Pharmacol. 1993. PMID: 7523772 Clinical Trial.
Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Coronary Artery Restenosis Prevention on Repeated Thromboxane Antagonism (CARPORT) Study Group.
Rensing BJ, Hermans WR, Vos J, Tijssen JG, Rutch W, Danchin N, Heyndrickx GR, Mast EG, Wijns W, Serruys PW. Rensing BJ, et al. Circulation. 1993 Sep;88(3):975-85. doi: 10.1161/01.cir.88.3.975. Circulation. 1993. PMID: 8353925 Clinical Trial.
Usefulness of quantitative and qualitative angiographic lesion morphology, and clinical characteristics in predicting major adverse cardiac events during and after native coronary balloon angioplasty. CARPORT and MERCATOR Study Groups.
Hermans WR, Foley DP, Rensing BJ, Rutsch W, Heyndrickx GR, Danchin N, Mast G, Hanet C, Lablanche JM, Rafflenbeul W, et al. Hermans WR, et al. Among authors: rensing bj. Am J Cardiol. 1993 Jul 1;72(1):14-20. doi: 10.1016/0002-9149(93)90211-t. Am J Cardiol. 1993. PMID: 8517422 Clinical Trial.
193 results